Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    10,988 result(s) found. Displaying page 269 of 550.
    «« First « Previous 265  266  267  268  269  270  271  272  273  Next» Last»»
    EudraCT Number: 2007-002472-34 Sponsor Protocol Number: EGF109462 Start Date*: 2007-08-06
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer
    Medical condition: Patients with advanced or metatstatic Non-Small Cell Lung Cancer who have received one prior platinum containing chemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002090-31 Sponsor Protocol Number: CAT-354-0603 Start Date*: 2007-09-26
    Sponsor Name:MedImmune Limited
    Full Title: A double-blind, placebo-controlled parallel-group study to assess the efficacy, safety, and tolerability of CAT-354
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004669-17 Sponsor Protocol Number: CSTI571E2205 Start Date*: 2008-02-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis
    Medical condition: Skin fibrosis in systemic sclerosis patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004875-21 Sponsor Protocol Number: BAY 43-9006 / 12913 Start Date*: 2008-01-21
    Sponsor Name:Bayer Healthcare AG, D-51368 Leverkusen, Germany
    Full Title: A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Rena...
    Medical condition: renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005234-36 Sponsor Protocol Number: NR001-03 Start Date*: 2008-11-20
    Sponsor Name:NovaRx Corporation
    Full Title: Registration Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix™...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000876-26 Sponsor Protocol Number: CLIN801 PCM201 Start Date*: 2008-05-02
    Sponsor Name:STEBA BIOTECH NV
    Full Title: "VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCE"
    Medical condition: The Treatment of prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing) GB (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005933-12 Sponsor Protocol Number: E7080-G000-201 Start Date*: 2009-10-29
    Sponsor Name:Eisai Limited
    Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified...
    Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013097-40 Sponsor Protocol Number: NP031112-08B02 Start Date*: 2009-10-30
    Sponsor Name:Noscira S.A.
    Full Title: A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in t...
    Medical condition: Mild to Moderate Progressive Supranuclear Palsy
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036813 Progressive supranuclear palsy LLT
    12.0 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010198-19 Sponsor Protocol Number: CLCQ908A2204 Start Date*: 2009-05-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL ch...
    Medical condition: Obesity and mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Completed) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015773-12 Sponsor Protocol Number: 6096-011 Start Date*: 2010-01-08
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period Adaptive Crossover Polysomnography Study to Evaluate the Safety and Efficacy of MK 6096 in Patients with Primary Ins...
    Medical condition: Primary insomnia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036701 Primary insomnia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-001361-29 Sponsor Protocol Number: CLWP 001 2008 Start Date*: 2009-10-08
    Sponsor Name:EBMT (European group for Blood and Marrow Transplantation)
    Full Title: Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation
    Medical condition: chronic myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014415-12 Sponsor Protocol Number: MEA112997 Start Date*: 2010-01-04
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled ref...
    Medical condition: severe uncontrolled refractory asthma.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-003772-21 Sponsor Protocol Number: MPP111782 Start Date*: 2009-05-06
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A TWO-PART, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER STUDY TO INVESTIGATE THE USE OF MEPOLIZUMAB (SB-240563) IN REDUCING THE NEED FOR SURGERY IN SUBJECTS WITH SEVERE BILATERAL NAS...
    Medical condition: Nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028756 Nasal polyps LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014660-19 Sponsor Protocol Number: RDEA594-203 Start Date*: 2009-12-09
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Safety, Efficacy and Potential Pharmacokinetic Interaction of RDEA594 and Allopurinol in Gout Patients w...
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-006494-90 Sponsor Protocol Number: M06-807 Start Date*: 2008-11-24
    Sponsor Name:Abbvie Deutschland GmbH & Co. K.G.
    Full Title: A Multi-center, Open-label Study of the Human Anti−TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in ...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-011398-33 Sponsor Protocol Number: NN1250-3724 Start Date*: 2010-01-27
    Sponsor Name:Novo Nordisk A/S
    Full Title: BEGIN™: EASY AM A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013030-25 Sponsor Protocol Number: GE-067-007 Start Date*: 2010-05-12
    Sponsor Name:GE Healthcare Ltd. and its Affiliates
    Full Title: A Principal Open-Label Study to Compare the Brain Uptake of [18F]flutemetamol with Brain Amyloid Levels Determined Post-Mortem
    Medical condition: The subjects have a short life expectancy. GE-067-007 will determine the level of association between brain uptake of (18F)flutemetamol and brain amyloid levels. Assessments will be based on analy...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048669 Terminal state LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016713-20 Sponsor Protocol Number: CL2-20098-072 Start Date*: 2010-04-13
    Sponsor Name:Laboratorios Servier S.L.
    Full Title: Eficacia de agomelatina 25mg/día (con posibilidad de incremento a 50mg/día tras 8 semanas de tratamiento) por vía oral durante 16 semanas en pacientes con Trastorno Obsesivo Compulsivo // Efficacy...
    Medical condition: Trastorno Obsesivo Compulsivo // Obsessive-compulsive disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029898 Obsessive-compulsive disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019634-26 Sponsor Protocol Number: MPEX-209 Start Date*: 2011-05-24
    Sponsor Name:Mpex Pharmaceuticals, Inc.
    Full Title: A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients
    Medical condition: Pseudomonas aeruginosa infection in patients suffering from stable Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    14.0 10021881 - Infections and infestations 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Ongoing) IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023442-75 Sponsor Protocol Number: DB2114417 Start Date*: 2011-04-28
    Sponsor Name:GlaxoSmithKline
    Full Title: An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444
    Medical condition: Moderate/severe chronic obstructive pulmonary disease (COPD).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 265  266  267  268  269  270  271  272  273  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 10:47:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA